NJA-301

N/A

Report date: 2025/06/04 15:16:25

Base Information

Drug NameNJA-301
Drug Alias NameiPS-ɑβ T cellNJA-301
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy
Mechanisms of ActionInterleukin-13 receptor subunit alpha-2 modulatorsEpidermal growth factor receptor erbB1 modulators
TargetsInterleukin-13 receptor subunit alpha-2Epidermal growth factor receptor erbB1
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShinobi Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesShinobi Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A